Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Rastogi P, et al. Among authors: cicin i. J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9. J Clin Oncol. 2024. PMID: 38194616 Free PMC article.
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Bilici A, Olmez OF, Kaplan MA, Oksuzoglu B, Sezer A, Karadurmus N, Cubukcu E, Sendur MAN, Aksoy S, Erdem D, Basaran G, Cakar B, Shbair ATM, Arslan C, Sumbul AT, Sezgin Goksu S, Karadag I, Cicin I, Gumus M, Selcukbiricik F, Harputluoglu H, Demirci U. Bilici A, et al. Among authors: cicin i. Acta Oncol. 2023 Apr;62(4):381-390. doi: 10.1080/0284186X.2023.2202330. Epub 2023 Apr 21. Acta Oncol. 2023. PMID: 37083566
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Soo RA, Cho BC, Kim JH, Ahn MJ, Lee KH, Zimina A, Orlov S, Bondarenko I, Lee YG, Lim YN, Lee SS, Lee KH, Pang YK, Fong CH, Kang JH, Lim CS, Danchaivijitr P, Kilickap S, Yang JC, Arslan C, Lee H, Park SN, Cicin I. Soo RA, et al. Among authors: cicin i. J Thorac Oncol. 2023 Dec;18(12):1756-1766. doi: 10.1016/j.jtho.2023.08.017. Epub 2023 Oct 22. J Thorac Oncol. 2023. PMID: 37865896 Free article. Clinical Trial.
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
Bjartell A, Costa L, Kramer G, Zurawski B, Galli L, Werbrouck P, Ecke T, Parikh O, Bennamoun M, Garcia Freire C, Peer A, Ljungberg B, Cicin I, Smith E, Lukac M, Wapenaar R, Chowdhury S. Bjartell A, et al. Among authors: cicin i. Eur Urol Open Sci. 2022 Sep 17;45:12-22. doi: 10.1016/j.euros.2022.08.018. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36353661 Free PMC article.
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
Güner G, Aktaş BY, Başal FB, Demirkazık A, Gürsoy P, Demirci U, Erman M, Yumuk PF, Şenler FÇ, Çakar B, Çiçin İ, Öztürk A, Coşkun HŞ, Çubukçu E, Işıkdoğan A, Ölmez ÖF, Tatlı AM, Karaağaç M, Şakalar T, Eralp Y, Korkmaz T, Kılıçkap S. Güner G, et al. Among authors: cicin i. J Cancer Res Clin Oncol. 2023 Nov;149(14):13271-13277. doi: 10.1007/s00432-023-05190-3. Epub 2023 Jul 22. J Cancer Res Clin Oncol. 2023. PMID: 37480524
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Cho BC, et al. Among authors: cicin i. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379502 Clinical Trial.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüş M, Chen CI, Ivanescu C, Kilickap S, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Harnett J, Mastey V, Naumann U, Reaney M, Konidaris G, Sasane M, Brady KJS, Li S, Gullo G, Rietschel P, Sezer A. Gümüş M, et al. Among authors: cicin i. Cancer. 2023 Jan 1;129(1):118-129. doi: 10.1002/cncr.34477. Epub 2022 Oct 29. Cancer. 2023. PMID: 36308296 Free PMC article. Clinical Trial.
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Cho BC, et al. Among authors: cicin i. J Thorac Oncol. 2023 Dec;18(12):1731-1742. doi: 10.1016/j.jtho.2023.08.018. Epub 2023 Aug 18. J Thorac Oncol. 2023. PMID: 37597750 Free article. Clinical Trial.
191 results